Supernus Shares Tumble 20% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
The stock was down 20% in premarket trading Wednesday. This biopharmaceutical company's stock is up 9.9% this year.
Supernus said results from the study didn't demonstrate statistically significant improvement on the primary endpoint of reduction in depressive symptoms compared to a placebo. The company added SPN-820 was well-tolerated with few adverse events.
President and Chief Executive Officer Jack Khattar said Supernus will continue to analyze data from the study and discuss the program's future with its development partner Navitor Pharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10